Home » Dana Goldman

About Dana Goldman

Dana Goldman is a Professor and the Leonard D. Schaeffer Director’s Chair at the University of Southern California. Until Fall 2009, he held RAND’s Distinguished Chair in Health Economics and directed RAND’s program in Economics, Finance, and Organization. He is also an Adjunct Professor of Health Services and Radiology at UCLA. More information about Dana can be found here.

Articles

Election verdict: Pharma Needs a New Prescription

Dana Goldman and Darius Lakdawalla provide a policy prescription list for the pharmaceutical industry aimed at improving access for patients today without discouraging investments into tomorrow’s medical innovations.  (more…)

Hooked in Hospitals: Many Medicare Patients Received First Painkillers There

Understanding the context of opioid providing, provider patterns, and patient behavior is the first step to developing policies that will adequately halt this pressing public health crisis. Two studies co-written by Schaeffer Center researchers analyze this context within the Medicare population. (more…)

Predicting the Economic Impact of Changes to Population Health

So much of health care policy is decided by the science of the educated guess, with “what-if” forecasts at the heart of any analysis. (more…)

The Baby Boomers Will Shift the Health Status of the Medicare Population

A Typical Medicare Recipient in 2030

A new study by Schaeffer Center researchers Etienne Gaudette, Bryan Tysinger, and Dana Goldman predicts significant changes in the average future Medicare recipient. (more…)

For Vulnerable Populations, the Medicare Part D Doughnut Hole Disrupts Medication Adherence

During the annual Medicare Open Enrollment period, senior citizens (more…)

Medicare’s Big Fat Problem, Fiscal and Otherwise

Co-Authors: Dana Goldman, Bryan Tysinger, and Alwyn Cassil

You can’t draw a straight line between growing Medicare spending and expanding American waistlines. But policymakers would be wise to keep both in mind as they ponder how to pay for the health care of 75-million-plus baby boomers who likely will live longer in worse health thanks to rising rates of chronic conditions, (more…)

The US Hospital System May Be Outperforming Expectations

In a new Health Affairs article released in February, Schaeffer Center researchers provide evidence that hospital productivity increased from 2002 to 2011, suggesting that the US health care system could be performing better than many believe.  John Romley, Research Assistant Professor at the USC Schaeffer Center for Health (more…)

Benefits of Robotic-Assisted Surgery for Kidney Cancer Far Outweigh Investment Costs

The benefits of robotically-assisted surgery for patients with kidney cancer outweigh the healthcare and surgical costs by a ratio of five to one. This is according to new research published in Health Affairs(more…)

Five Myths About Cancer Care in America

One of the most pervasive and misguided myths about cancer is that the ‘war on cancer’ has been a failure. With provocative news headlines about cancer often popping up, it is understandable that there is public uncertainty about progress in its treatment and patient care. (more…)

Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform

The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement. (more…)

To Prevent Another EpiPen Controversy, the Government Should Step In

The real problem is with lax regulatory oversight that doesn’t ensure an adequate supply of drugs critical to population health and opens the door to shocking price increases.  (more…)

What the candidates don’t get about drug prices

If you are like me, you are watching with relish the presidential debates on both the Republican and Democratic side. Sometimes, amid the reality show-type theatrics, they actually substantive discussions about issues like Social Security, (more…)

Biomedical Research in the Age of Preventive Medicine

“Moonshot” was the word Google CEO Larry Page used to describe his newest venture, Calico–a biotech startup focused on the challenge of aging and age-associated pathology. In fact, medical therapies to delay aging are increasingly feasible, and, as shown by our study in Health Affairs, could achieve a far greater return on investment than comparable advances in the treatment of specific diseases. (more…)

Where Obamacare Went Wrong (Or Did It?)

By now, everyone has formed opinions of the Affordable Care Act (ACA). Ironically, the strongest opinions seem to come from people that know the least about it. (more…)

Don’t Be Fooled by Claims About the ACA Impact on Insurance Premiums

A recent New York Times headline reported that health plan costs for New Yorkers will fall 50%. They were taking the bait from Governor Cuomo’s office, who crowed about “real competition that helps drive down health insurance costs.” (more…)

What Health Care Can Learn from Netflix

Watching Arrested Development with my kids, my mind started to wander after the eighth episode or so. How can Netflix let us gorge ourselves on so much television and – if it makes business sense – are there any lessons for the health care industry? The surprising answer turns out be yes, and it has to do with drugs. (more…)

Don’t Blame the Medical Innovators

Health economists are fond of saying that medical technology is to blame for rising health care costs. Some – including me – have also pointed out that about 30% of health care spending is wasteful. (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook




Subscribe to receive updates